Original Article

**Pretreatment clinical prognostic factors for brain metastases from breast cancer treated with Gamma Knife radiosurgery**

Andrew T. Roehrig, Ethan A. Ferrel, Devon A. Benincosa, Alexander R. MacKay, Benjamin C. Ling, Jonathan D. Carlson, John J. Demakas, Aaron Wagner, Wayne T. Lamoreaux, Robert K. Fairbanks, Jason A. Call, Barton S. Cooke, Ben Peressini, Christopher M. Lee

1Gamma Knife of Spokane, 910 W 5th Ave, Suite 102, Spokane, WA 99204, 1Cancer Care Northwest, 910 W 5th Ave, Suite 102, Spokane, WA 99204, 1University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, 1Inland Neurosurgery and Spine Associates, 105 W 8th Ave, Suite 200, 1Department of Neurosurgery, Rockwood Clinic, 801 W 5th Ave, Suite 525, Spokane, WA 99204, 4DataWorks Analytics, LLC, 3952 N Magnuson St, Coeur D’Alene, ID 83815, USA

E-mail: Andrew T. Roehrig - roehriat@uw.edu; Ethan A. Ferrel - ferrele@uw.edu; Devon A. Benincosa - devonbenincosa@hotmail.com; Alexander R. MacKay - gkspokane@armackay.net; Benjamin C. Ling - benjamin.ling@providence.org; Jonathan D. Carlson - JCarlson@neuroandspine.com; John J. Demakas - JDemakas@rockwoodclinic.com; Aaron Wagner - aaron.wagner@ccnw.net; Wayne T. Lamoreaux - wayne.lamoreaux@ccnw.net; Robert K. Fairbanks - fairbrk@ccnw.net; Jason A. Call - jason.call@ccnw.net; Barton S. Cooke - bo@gkspokane.com; Ben Peressini - benperessini@dataworksnw.com; *Christopher M. Lee - chris.lee@ccnw.net

*Corresponding author

Received: 28 February 16   Accepted: 08 August 16   Published: 14 November 16

**Abstract**

**Background:** Brain metastases significantly affect morbidity and mortality rates for patients with metastatic breast cancer. Treatment for brain metastases lengthens survival, and options such as stereotactic radiosurgery (SRS) can increase survival to 12 months or longer. This study retrospectively analyzes the prognostic factors for overall survival (OS) for patients with one or multiple brain metastases from breast cancer treated with SRS.

**Methods:** Between December 2001 and May 2015, 111 patients with brain metastases from breast cancer were grouped by potential prognostic factors including age at diagnosis, Karnofsky Performance Status (KPS) score, number of brain metastases, and whether or not they received adjuvant treatments such as whole brain radiotherapy (WBRT) or surgical resection. Survival rates were determined for all groups, and hazard ratios were calculated using univariate and multivariate analyses to compare differences in OS.

**Results:** Median OS was 16.8 ± 4.22 months. Univariate analysis of patients with a KPS ≤ 60 and multivariate analysis of KPS 70–80 showed significantly shorter survival than those with KPS 90–100 (5.9 ± 1.22 months, 21.3 ± 11.69 months, and 22.00 ± 12.56 months, \( P = 0.024 \) and < 0.001). Other results such as age ≥ 65 years and higher number of brain metastases trended toward shorter survival but were not statistically significant. No difference in survival was found for patients who had received WBRT in addition to SRS (\( P = 0.779 \)).

How to cite this article: Roehrig AT, Ferrel EA, Benincosa DA, MacKay AR, Ling BC, Carlson JD, et al. Pretreatment clinical prognostic factors for brain metastases from breast cancer treated with Gamma Knife radiosurgery. Surg Neurol Int 2016;7:S830-6.

http://surgicalneurologyint.com/Pretreatment-clinical-prognostic-factors-for-brain-metastases-from-breast-cancer-treated-with-Gamma-Knife-radiosurgery/
INTRODUCTION

Brain metastases are the number one cause of morbidity and mortality for approximately 1.4 million Americans who are diagnosed with cancer every year. An estimated 20%–40% of those diagnosed with cancer will develop brain metastases over the course of their illness. Breast cancer remains the second most common origin of intracranial metastases behind lung cancer, with 10%–16% of breast cancer patients developing brain metastases. The prognosis of these patients is generally poor: untreated patients survive an average of just 1 month. Radiotherapy in the form of whole brain radiation therapy (WBRT) alone can extend breast cancer brain metastases (BCBM) survival to 3–4 months, and surgical resection of a tumor and/or use of radiosurgery can extend that to an average of 7–12 months. Prognosis of longer survival is indicated by several factors such as Karnofsky Performance Status (KPS) score >70, age <60 years, and a single small metastasis or small total volume of metastases.

The clinical approach to managing brain metastases comprises one or several modalities including chemotherapy, surgical resection, WBRT, and stereotactic radiosurgery (SRS). The effectiveness of radiosurgery in treating brain metastases has been well documented, and several methods are available for delivery of radiation. These equipment include linear accelerators, tomotherapy, cyclotrons, and cobalt-60-based Gamma Knife. To date, there are several retrospective studies that outline some prognostic factors associated with radiosurgery treatment of BCBM. Much of the literature is focused on breast cancer subtype and histology, specifically how human epidermal growth factor receptor 2 (HER2)-positive, triple-negative, and estrogen receptor/progesterone receptor-positive subtypes differ in their overall survival (OS) prognostic ability. Other studies have focused on adjuvant treatment options such as trastuzumab and lapatinib.

In this study, we offer 111 retrospectively analyzed data from patients with BCBM treated with Gamma Knife radiosurgery (GKRS) at Gamma Knife of Spokane. Our goal is to outline several pretreatment clinical factors that have effects on prognosis for patients undergoing treatment.

MATERIALS AND METHODS

For this analysis, we examined 111 patients with a diagnosis of brain metastasis and primary tumor histology of breast cancer. These patients were treated between December 2001 and May 2015 by physicians at Gamma Knife of Spokane. The patients were grouped by age at brain metastasis diagnosis (<65, 65+) by whether or not they received whole brain irradiation (WBI), by whether or not they underwent resection, by KPS value, and by the number of brain metastases (1, 2–5, >5). Number of patients in these groups are shown in Table 1.

Survival curves were estimated using the Kaplan–Meier method and used to compare treatment groups, age groups, KPS groups, and brain metastases number groups. Andersen confidence intervals of 95% were constructed for the median survival time of the groups. An estimate of the standard error was used to calculate approximate confidence intervals for the log-hazard ratio (HR).

**Table 1: Patient population baseline characteristics**

| Characteristic | Total (n=111) |
|----------------|--------------|
| Age at diagnosis |              |
| <65            | 82           |
| ≥65           | 27           |
| Unknown        | 2            |
| KPS            |              |
| 90-100         | 12           |
| 70-80          | 16           |
| ≤60            | 9            |
| Unknown        | 74           |
| Brain metastases |            |
| 1              | 37           |
| 2-5           | 36           |
| >5            | 35           |
| Unknown        | 3            |
| Received WBI   |              |
| No            | 53           |
| Yes           | 58           |
| Underwent resection |        |
| No            | 95           |
| Yes           | 16           |

KPS: Karnofsky Performance Status, WBI: Whole brain irradiation
To determine whether there is statistical evidence of differences between the survival curves of the groups, log-rank tests were employed. The multivariate analysis of the treatment groups, age groups, KPS groups, and brain metastases number groups used the Cox proportional hazard model. All statistical analyses utilized StatsDirect version 2.8.0 (StatsDirect Ltd., Altrincham, UK) and SigmaPlot version 11.0 (SYSTAT Software, Inc., San Jose, CA, USA).

RESULTS

A total of 111 patients were included in the study. Their baseline characteristics are shown in Table 1. There were 82 (73.8%) patients younger than 65 years. The number of patients who were diagnosed with 1, 2–5, and 5+ brain metastases were 37 (33.3%), 36 (32.4%), and 35 (31.5%), respectively. Thirty-seven (35.3%) patients had recorded KPS scores, but 74 (66.7%) did not have KPS scores. About half of the patients (52.2%) received whole brain radiation and 16 (14.4%) patients underwent surgical resection.

Median OS was $16.8 \pm 4.22$ months. Kaplan–Meier survival curves for several treatment groups are found in Figures 1-3. Figure 1 shows age-related survival curves for patients $>65$ or $65+$. Although not statistically significant, the median survival of those patient groups was $19.0 \pm 4.77$ months and $15.1 \pm 7.74$ months, respectively ($P = 0.633$) [Table 2]. Figure 2 shows KPS score survival. Significant differences in survival were demonstrated between patients with KPS of 90–100, those of KPS 70–80, and those of KPS 60 and below ($P > 0.001$). Higher KPS correlated statistically with an increased survival rate. Figure 3 shows survival for the number of brain metastases: 1, 2–5, and 5+. No significantly different survival was indicated in those patient groups ($P = 0.349$ and 0.288, respectively).

Univariate median survival confidence interval and HR confidence intervals are shown in Table 2. Within each category, a reference group was selected against which the other groups’ HRs were tested. The univariate analysis indicated patients with KPS = 60–70 had survival experience that was statistically significantly different ($P = 0.024$) than the reference group (KPS = 90–100).

The multivariate analysis HR estimates and confidence intervals are shown in Table 3. The multivariate analysis utilized the same reference groups as the univariate analyses against which the other groups’ HRs were tested. The multivariate analysis indicated patients with KPS = 70–80 and KPS $\leq$ 60 had survival experience that was significantly different than the reference group (KPS = 90–100).

Fifty-eight (52%) patients received WBRT in addition to SRS treatment. Median survival lengths for patients who did and did not receive WBRT were $16.8 \pm 8.14$ months and $19.0 \pm 6.46$ months, respectively. This was not a
significant difference upon multivariate or univariate analysis ($P = 0.779$ and 0.251, respectively).

Absolute survival rates are shown in Table 4. Six-month survival was 70.8%, 1-year survival was 59.5%, 2-year survival was 38.4%, and 5-year survival was 15.6%.

**DISCUSSION**

Brain metastases are less common than bone or other soft tissue metastases for patients with breast cancer, but they represent a significantly poorer prognosis and are often resistant to systemic therapies. Studies have shown that the median OS for patients with brain metastases following WBRT and SRS is between 4 and 6 months. Therefore, it is imperative that more effective methods of treatment should be developed to prolong and improve the quality of life of patients with this increasingly common disease. This study aims to retrospectively analyze the effectiveness of treatment of BCBM with GKRS and to identify which patients are most likely to benefit from treatment. Several key prognostic factors are outlined by the Radiation Therapy Oncology Group (RTOG) in 1989, and revised again in 1997 to include recursive partitioning analysis (RPA) classes. These factors were associated with positive survival and include KPS score of at least 70, age < 65, and low number of brain metastases (between 1 and 4). To assess the effectiveness of treatment, we compared OS of patients receiving any combination of GKRS and whether they had adjuvant treatment such as surgical resection or WBRT.

Our study found that KPS score was a significant prognostic factor. Patients with lower KPS score on the day of treatment had significantly shorter survival than did those with high functionality. This is consistent with other reports of KPS as a strong predictor of survival for patients undergoing SRS. Kased et al. found that KPS score was a significant prognostic factor in both univariate and multivariate analyses for the 176 patients treated with radiosurgery or radiosurgery plus WBRT. They found that those with a KPS score of 70 or greater had significantly longer survival versus those with a KPS score of less than 70 ($P = 0.005$). This is supported by a long history of studies that demonstrate KPS is a significantly important prognostic indicator for patients with BCBM.

---

**Table 2: Univariate median survival estimates (months) and hazard ratios of patients**

|                        | Median survival | HR   | 95% CI       | Estimate | 95% CI     | **P** |
|------------------------|-----------------|------|--------------|----------|------------|-------|
| **Age at diagnosis**   |                 |      |              |          |            |       |
| < 65*                  | 82              | 19.00±4.77 | Reference   | 1.17     | 0.60-2.15  | 0.633 |
| ≥ 65                   | 27              | 15.10±7.74 | 1.88        | 0.22-7.41| 0.300      |       |
| Unknown                | 2               | 2.80±incalculable | Reference   | 1.17     | 0.60-2.15  | 0.633 |
| **KPS**                |                 |      |              |          |            |       |
| 90-100*                | 12              | 22.00±12.56 | Reference   | 1.17     | 0.60-2.15  | 0.633 |
| 70-80                  | 16              | 21.3±11.69 | 4.13        | 1.16-16.45| 0.024      |       |
| ≤ 60                   | 9               | 5.90±1.22  | 1.38        | 0.62-3.63 | 0.425      |       |
| Unknown                | 74              | 14.7±7.66  | 3.57        | 1.16-16.45| 0.024      |       |
| **Brain metastases**   |                 |      |              |          |            |       |
| 1*                     | 37              | 19.10±18.01 | Reference   | 1.17     | 0.60-2.15  | 0.633 |
| 2-5                    | 36              | 14.70±5.29 | 1.28        | 0.70-2.40 | 0.468      |       |
| > 5                    | 35              | 14.10±9.14 | 1.45        | 0.78-2.72 | 0.237      |       |
| Unknown                | 3               | 3.70±0.16  | 2.41        | 0.43-8.91 | 0.164      |       |
| **WBI received**       |                 |      |              |          |            |       |
| No*                    | 53              | 19.00±6.46 | Reference   | 1.17     | 0.60-2.15  | 0.633 |
| Yes                    | 58              | 16.80±8.14 | 3.10        | 0.59-3.106| 0.251      |       |
| **Resection undergone**|                 |      |              |          |            |       |
| No*                    | 95              | 15.10±5.00 | Reference   | 1.17     | 0.60-2.15  | 0.633 |
| Yes                    | 16              | 24.20±18.57 | 0.67        | 0.31-1.32 | 0.296      |       |

*Reference group against which other groups' survival experience are compared, **P value for log-rank testing, the null hypothesis that the groups' survival experience is same as reference group. KPS: Karnofsky Performance Status, HR: Hazard ratio, WBI: Whole brain irradiation
They were not significant indicators of prognosis, contrary to the RTOG findings, but rather tumor subtype and KPS status remained strong indicators of OS for breast cancer patients with brain metastases. Our study did not find significance in either univariate or multivariate analysis between patients aged 65 years and older and those younger than 65 years in terms of OS (P = 0.633). This supports the findings of Sperduto et al. in a single-institutional community setting. However, our study cohort showed that the included BCBM patients younger than 65 years (73%) had a slightly longer median survival than those 65 or older, at 19.0 months and 15.1 months, respectively [Table 1].

Our multivariate survival analyses also looked at adjuvant therapies over the course of the patient’s treatment, specifically the addition of surgical resection or WBRT to SRS. The literature is generally in agreement that while the addition of SRS to WBRT may improve intracranial recurrence rates, there is no significant difference in OS for patients with brain metastases from varying tumor etiologies.21,27,31 These findings were supported by two randomized controlled trials by Aoyama et al. and Chang et al., who found that survival did not significantly differ between the use of WBRT plus SRS compared to SRS alone.3,7,15 With regard to patients with breast cancer-specific brain metastases, some older studies have demonstrated that a whole brain radiation dose ≥30 Gy is a significant prognostic indicator.8

Our study found that there was no significant difference in OS between patients who received WBRT or surgical resection treatments in addition to SRS (P = 0.779 and P = 0.42, respectively). This finding may have biases typically associated with retrospective studies, such as that patients who received WBRT may have had more brain metastases or patients who received surgical resection may have had fewer metastases that were surgically accessible. This finding is also in agreement with the breast-GPA model developed by Sperduto et al. Although the GPA guidelines are intended to inform treatment decisions, they analyzed the data with intact therapies over the course of the patient’s treatment.

Radiosurgery is also recently being used for patients with a greater number of metastases, and deferral of WBRT has become the standard of care for many patients.4,7,20 One retrospective study by Amendola et al. evaluated patients with breast carcinoma brain metastases who were treated with SRS.2 Sixty-eight patients received a total of 110 treatments to an average of 8 tumors per patient, with a median follow-up of 7.8 months. No evidence of radiation-induced dementia was noted, and survival was not significantly correlated to the number of brain metastases treated. Shultz et al. retrospectively analyzed 95 patients with 652 metastases (range, 1–14) who received multiple treatments of SRS for recurrent intracranial metastases.29 The study found that overall performance status and tumor volume, but not number of tumors, were critical in selecting patients who would do well with repeat SRS as opposed to WBRT. Local failure and OS rates were found to be consistent with numbers reported in the literature.7,30,36

Presence of extracranial disease is often used as a prognostic indicator for brain metastasis OS. In breast cancer, this

### Table 3: Multivariate hazard ratios, confidence intervals, and P values

| Age at diagnosis | n     | HR Estimate | 95% CI          | P**  |
|------------------|-------|-------------|-----------------|------|
| < 65*            | 82    | Reference   |                 |      |
| ≥ 65             | 27    | 1.22        | 0.66-2.23       | 0.527|
| Unknown          | 2     | 0.61        | 0.12-3.20       | 0.561|

### Table 4: Absolute survival rates at 0.5, 1, 2, and 5 years

| Year | Survival rate | 95% CI         |
|------|---------------|----------------|
| 0.5  | 70.7          | 61.0-78.8      |
| 1    | 59.5          | 49.4-68.3      |
| 2    | 38.4          | 28.7-48.1      |
| 5    | 15.6          | 7.9-25.7       |

Primary tumor were all significant prognostic factors on multivariate analysis.3

Breast cancer-specific prognostic factors may differ from those of other tumor types, according to recent studies differentiating BCBM OS from other intracranial metastases. In 2012, Sperduto et al. published seminal work describing a modified graded prognostic assessment (GPA) for breast-specific cancers.33 They found that age and number of brain metastases were not significant indicators of prognosis, contrary to the RTOG findings, but rather tumor subtype and KPS status remained strong indicators of OS for breast cancer patients with brain metastases. Our study did not find significance in either univariate or multivariate analysis between patients aged 65 years and older and those younger than 65 years in terms of OS (P = 0.633). This supports the findings of Sperduto et al. in a single-institutional community setting. However, our study cohort showed that the included BCBM patients younger than 65 years (73%) had a slightly longer median survival than those 65 or older, at 19.0 months and 15.1 months, respectively [Table 1].

Our multivariate survival analyses also looked at adjuvant therapies over the course of the patient’s treatment, specifically the addition of surgical resection or WBRT to SRS. The literature is generally in agreement that while the addition of SRS to WBRT may improve intracranial recurrence rates, there is no significant difference in OS for patients with brain metastases from varying tumor etiologies.21,27,31 These findings were supported by two randomized controlled trials by Aoyama et al. and Chang et al., who found that survival did not significantly differ between the use of WBRT plus SRS compared to SRS alone.3,7,15 With regard to patients with breast cancer-specific brain metastases, some older studies have demonstrated that a whole brain radiation dose ≥30 Gy is a significant prognostic indicator.8

Our study found that there was no significant difference in OS between patients who received WBRT or surgical resection treatments in addition to SRS (P = 0.779 and P = 0.42, respectively). This finding may have biases typically associated with retrospective studies, such as that patients who received WBRT may have had more brain metastases or patients who received surgical resection may have had fewer metastases that were surgically accessible. This finding is also in agreement with the breast-GPA model developed by Sperduto et al. Although the GPA guidelines are intended to inform treatment decisions, they analyzed the data with intact therapies over the course of the patient’s treatment.

Radiosurgery is also recently being used for patients with a greater number of metastases, and deferral of WBRT has become the standard of care for many patients.4,7,20 One retrospective study by Amendola et al. evaluated patients with breast carcinoma brain metastases who were treated with SRS.2 Sixty-eight patients received a total of 110 treatments to an average of 8 tumors per patient, with a median follow-up of 7.8 months. No evidence of radiation-induced dementia was noted, and survival was not significantly correlated to the number of brain metastases treated. Shultz et al. retrospectively analyzed 95 patients with 652 metastases (range, 1–14) who received multiple treatments of SRS for recurrent intracranial metastases.29 The study found that overall performance status and tumor volume, but not number of tumors, were critical in selecting patients who would do well with repeat SRS as opposed to WBRT. Local failure and OS rates were found to be consistent with numbers reported in the literature.7,30,36

Presence of extracranial disease is often used as a prognostic indicator for brain metastasis OS. In breast cancer, this
prognostic value may be limited in part due to the success of systemic therapy. This is especially true since the era of trastuzumab therapy for HER2-positive breast cancers. For intracranial metastases, low levels of trastuzumab penetrate the blood–brain barrier, but this effect can be somewhat overcome after treatment with WBRT. More recently, capcitabine and lapatinib have been shown to have significant central nervous system concentrations and improve OS in previously untreated patients of HER2-positive cancers with brain metastases. Our study was not able to assess the presence of extracranial disease in our retrospective data set, but future studies should attempt to include these data.

Our study is inherently limited due to its retrospective nature. The patients who were selected for GKRS may have had better prognosis than other BCBM patients who were ineligible for SRS treatment. Because this study is not a randomized controlled trial, it has limited scope for informing clinical practice. It does, however, suggest that patients with BCBM who have good performance status (KPS ≥70) may have increased survival, despite other negatively influencing factors such as age ≥65 or multiple brain metastases. In addition, KPS scores were only available for 37 patients (33%), even though this remained our strongest predictive factor.

CONCLUSION

Our study suggests that patients with BCBM who have good performance status (KPS ≥70) may have increased survival, despite other negatively influencing factors such as age ≥65 or multiple brain metastases. In this report, the best OS rates were statistically associated with a KPS of 90 or greater. We did not find any significant survival benefit to the addition of WBRT or surgery to SRS treatment on univariate or multivariate analysis. We found encouraging long-term survival for some patients, with 15% of our cohort reaching the 5-year survival mark.

Each BCBM patient and his/her family should be informed of all treatment options and of the risks and benefits associated with each. Individual preferences and goals should also be a considered factor for physicians treating BCBM patients. SRS therapy provides the most benefit for patients with good performance status upon diagnosis of brain metastases. Repeated treatments may also be beneficial for patients who continue to have good performance status and a low gross tumor volume. GKRS continues to be a safe and effective treatment option to manage brain metastases with focal radiotherapy.

Acknowledgment

We would like to acknowledge Eric Reynolds and Jill Adams for their help and support, as well as the entire Gamma Knife of Spokane and Cancer Care Northwest research staff, for their contributions to this manuscript.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Akbayrek S, Chang EL, Mahajan A, Hassenbusch SJ, Allen PK, Mathews LA, et al. Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am J Clin Oncol 2007;30:310-4.
2. Amendola BE, Wolf AL, Coy SR, Amendola M, Bloch L. Gamma knife radiosurgery in the treatment of patients with single and multiple brain metastases from carcinoma of the breast. Cancer J 2000;6:88-92.
3. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyota T, Hatan K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006;295:2483-91.
4. Aoyama H, Tago M, Kato N, Toyota T, Kenjo M, Hirota S, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007;68:1388-95.
5. Aversa C, Rossi V, Geuna E, Martinello R, Miliani A, Redana S, et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast 2014;23:623-8.
6. Bachelot T, Romieu G, Campone M, Dieras V, Crocet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 2013;14:64-71.
7. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornbluth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiotherapy plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 2009;10:1037-44.
8. Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: A single-institution review. Cancer 2010;116:3084-92.
9. de Azevedo Santos TR, Tundisi CF, Ramos H, Maia MA, Pellizzon AC, Silva ML, et al. Local control after radiosurgery for brain metastases: Predictive factors and implications for clinical decision. Radiat Oncol 2015;10:63.
10. Diener-West M, Dobbins TW, Philips TL, Nelson DF. Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys 1989;16:669-73.
11. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: The importance of HER-2 status. Cancer 2008;112:2359-67.
12. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
13. Gavrilovic IT, Posner JB. Brain metastases: Epidemiology and pathophysiology. J Neurooncol 2005;75:5-14.
14. Goyal S, Prasad D, Harrell F Jr., Matsumoto J, Rich T, Steiner L. Gamma knife surgery for the treatment of intracranial metastases from breast cancer. J Neurosurg 2005;103:218-23.
15. Hasegawa T, Kondziolka D, Flickinger JC, Germanwala A, Lunsford LD. Brain metastases: Epidemiology and pathophysiology. J Neurooncol 2005;75:1-14.
16. Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, et al. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: A multicenter retrospective analysis. Breast Cancer Res Treat 2015;149:277-84.
17. Iuchi T, Shingyoji M, Sakaia T, Hatan K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 2013;82:282-7.
18. Kased N, Binder DK, McDermott MW, Nakamura JL, Huang K, Berger MS,.
et al. Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiat Oncol Biol Phys 2009;75:1132-40.

19. Klos KJ, O’Neill BP. Brain metastases. Neurologist 2004;10:31-46.

20. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-41.

21. Kondziolka D, Kano H, Harrison GL, Yang HC, Liew DN, Niranjan A, et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article. J Neurosurg 2011;114:792-800.

22. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17.

23. Muacevic A, Kreth FW, Tonn JC, Wowra B. Stereotactic radiosurgery for multiple brain metastases from breast carcinoma. Cancer 2004;100:1705-11.

24. Newton HB. Chemotherapy for the treatment of metastatic brain tumors. Expert Rev Anticancer Ther 2002;2:495-506.

25. Nieder C, Grosu AL, Gaspar LE. Stereotactic radiosurgery (SRS) for brain metastases: A systematic review. Radiat Oncol 2014;9:155.

26. Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: Differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010;21:942-8.

27. Rades D, Kuester JD, Veninga T, Gliemroth J, Schild SE. Whole brain radiotherapy plus stereotactic radiosurgery (WBRT SRS) versus surgery plus whole brain radiotherapy (OP WBRT) for 1-3 brain metastases: Results of a matched pair analysis. Eur J Cancer 2009;45:400-4.

28. Serna A, Escolar PP, Puchades V, Mata F, Ramos D, Gómez MA, et al. Single fraction volumetric modulated arc radiosurgery of brain metastases. Clin Transl Oncol 2015;17:596-603.

29. Shultz DB, Modlin LA, Jayachandran P, Von Eyben R, Gibb IC, Choi CY, et al. Repeat courses of stereotactic radiosurgery (SRS), deferring whole-brain irradiation, for new brain metastases after initial SRS. Int J Radiat Oncol Biol Phys 2015;92:993-9.

30. Shuto T, Fujino H, Inomori S, Nagano H. Repeated gamma knife radiosurgery for multiple metastatic brain tumours. Acta Neurochir (Wien) 2004;146:989-93.

31. Sneed PK, Suh JH, Goetsch SJ, Sanghavi SN, Chappell R, Buatti JM, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002;53:519-26.

32. Soffietti R, Rudà R, Trevisan E. Brain metastases: Current management and new developments. Curr Opin Oncol 2008;20:676-84.

33. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 2012;82:2111-7.

34. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18:23-8.

35. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-20.

36. Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Watanabe S, et al. Stereotactic radiosurgery for patients with multiple brain metastases: A case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors. J Neurosurg 2014;121(Suppl 2):16-25.